(P-1090) Rifaquizinone for the Treatment of Acute Bacterial Skin and Skin Structure Infections: A Multicenter, Double-Blind, Randomized, Active-Controlled, Phase 2 Trial

Friday, October 18, 2024

12:15 PM – 1:30 PM US PT

Location: Halls JK

Co-Author(s)

JO

J. Scott Overcash, MD

Velocity Clinical Research
San Diego, California, United States
MW

Michael Waters, MD

Velocity Clinical Research
Chula Vista, California, United States
Huan Wang, PhD (she/her/hers)

Director of pharmacology and toxicology
TenNor Therapeutics (Suzhou) Ltd
Suzhou, Jiangsu, China (People's Republic)
GG

Guozhu Geng, MD

TenNor Therapeutics (Suzhou) Ltd
Suzhou, Jiangsu, China
CA

Changlin Ai, Master of Medicine

TenNor Therapeutics (Suzhou) Ltd
Suzhou, Jiangsu, China
Zhenkun Ma, PhD (he/him/his)

CEO
TenNor Therapeutics
Suzhou Industrial Park, Jiangsu, China (People's Republic)

Jing Chen, Master of Science (she/her/hers)

VP Clinical Operation
TenNor Therapeutics （Suzhou） Ltd
Suzhou, Jiangsu, China (People's Republic)